SG11201600846WA - Substituted imidazoles as n-type calcium channel blockers - Google Patents
Substituted imidazoles as n-type calcium channel blockersInfo
- Publication number
- SG11201600846WA SG11201600846WA SG11201600846WA SG11201600846WA SG11201600846WA SG 11201600846W A SG11201600846W A SG 11201600846WA SG 11201600846W A SG11201600846W A SG 11201600846WA SG 11201600846W A SG11201600846W A SG 11201600846WA SG 11201600846W A SG11201600846W A SG 11201600846WA
- Authority
- SG
- Singapore
- Prior art keywords
- calcium channel
- channel blockers
- type calcium
- substituted imidazoles
- imidazoles
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pregnancy & Childbirth (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2013/055282 WO2015023289A1 (en) | 2013-08-16 | 2013-08-16 | Substituted imidazoles as n-type calcium channel blockers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201600846WA true SG11201600846WA (en) | 2016-03-30 |
Family
ID=49034269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201600846WA SG11201600846WA (en) | 2013-08-16 | 2013-08-16 | Substituted imidazoles as n-type calcium channel blockers |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP3033337B1 (es) |
| JP (1) | JP6239113B2 (es) |
| KR (1) | KR20160043047A (es) |
| CN (1) | CN105658644B (es) |
| AU (1) | AU2013397913B2 (es) |
| CA (1) | CA2921298C (es) |
| EA (1) | EA029711B1 (es) |
| ES (1) | ES2665995T3 (es) |
| HK (1) | HK1223939A1 (es) |
| IL (1) | IL243683A0 (es) |
| MX (1) | MX2016002043A (es) |
| SG (1) | SG11201600846WA (es) |
| WO (1) | WO2015023289A1 (es) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9974775B2 (en) | 2013-08-16 | 2018-05-22 | Janssen Pharmaceutica Nv | Substituted imidazoles as N-type calcium channel blockers |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109535033A (zh) * | 2018-12-28 | 2019-03-29 | 天津阿尔塔科技有限公司 | 一种氟菌唑代谢物fm-6-1的合成方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0415165A (pt) * | 2003-10-01 | 2007-01-09 | Adolor Corp | composto heterocìclico espirocìclico, composição farmacêutica, método para ligar receptores opióides, métodos para prevenir ou tratar dor, disfunção gastrointestinal, um distúrbio do trato urogenital, um distúrbio imunomodulatório, um distúrbio inflamatório, um distúrbio de função respiratória, ansiedade, distúrbio do humor, um distúrbio relacionado a estresse, distúrbio do sistema nervoso simpático, tosse, e um distúrbio motor, método para tratar uma lesão traumática ao sistema nervoso central, métodos para prevenir ou tratar acidente vascular, arritmia cardìaca, glaucoma, e disfunção sexual, métodos para tratar uma condição selecionada do grupo consistindo de choque, edema cerebral, isquemia cerebral, déficit cerebral após cirurgia cardìaca (bypass) e enxerto, lupus eritematoso sistêmico, doença de hodgkin, doença de sjogren, epilepsia, e rejeição em transplantes de órgão e enxertos de pele, e para tratar dependência de substáncias, métodos para melhorar a sobrevivência de órgãos e células, e cardioproteção após infarto do miocárdio, métodos para reduzir a necessidade de anestesia, para produzir ou manter um estado anestésico, derivado radiomarcado de um composto, derivado isotopicamente marcado de um composto, composto e método de diagnóstico por imagem |
| BRPI0508594A (pt) * | 2004-03-08 | 2007-08-21 | Wyeth Corp | moduladores de canal de ìon |
| US7598261B2 (en) * | 2005-03-31 | 2009-10-06 | Adolor Corporation | Spirocyclic heterocyclic derivatives and methods of their use |
| JO3240B1 (ar) * | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
-
2013
- 2013-08-16 SG SG11201600846WA patent/SG11201600846WA/en unknown
- 2013-08-16 JP JP2016534561A patent/JP6239113B2/ja not_active Expired - Fee Related
- 2013-08-16 WO PCT/US2013/055282 patent/WO2015023289A1/en active Application Filing
- 2013-08-16 EA EA201690400A patent/EA029711B1/ru not_active IP Right Cessation
- 2013-08-16 ES ES13753067.1T patent/ES2665995T3/es active Active
- 2013-08-16 KR KR1020167006562A patent/KR20160043047A/ko not_active Application Discontinuation
- 2013-08-16 AU AU2013397913A patent/AU2013397913B2/en not_active Ceased
- 2013-08-16 CA CA2921298A patent/CA2921298C/en not_active Expired - Fee Related
- 2013-08-16 CN CN201380078912.4A patent/CN105658644B/zh not_active Expired - Fee Related
- 2013-08-16 MX MX2016002043A patent/MX2016002043A/es unknown
- 2013-08-16 EP EP13753067.1A patent/EP3033337B1/en active Active
-
2016
- 2016-01-19 IL IL243683A patent/IL243683A0/en unknown
- 2016-10-27 HK HK16112344.0A patent/HK1223939A1/zh unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9974775B2 (en) | 2013-08-16 | 2018-05-22 | Janssen Pharmaceutica Nv | Substituted imidazoles as N-type calcium channel blockers |
Also Published As
| Publication number | Publication date |
|---|---|
| JP6239113B2 (ja) | 2017-11-29 |
| IL243683A0 (en) | 2016-04-21 |
| WO2015023289A1 (en) | 2015-02-19 |
| CA2921298C (en) | 2021-07-27 |
| EA029711B1 (ru) | 2018-05-31 |
| EA201690400A1 (ru) | 2016-06-30 |
| CN105658644A (zh) | 2016-06-08 |
| AU2013397913A1 (en) | 2016-02-11 |
| CA2921298A1 (en) | 2015-02-19 |
| CN105658644B (zh) | 2018-10-02 |
| HK1223939A1 (zh) | 2017-08-11 |
| ES2665995T3 (es) | 2018-04-30 |
| JP2016528248A (ja) | 2016-09-15 |
| AU2013397913B2 (en) | 2018-07-19 |
| EP3033337A1 (en) | 2016-06-22 |
| EP3033337B1 (en) | 2018-02-28 |
| KR20160043047A (ko) | 2016-04-20 |
| MX2016002043A (es) | 2016-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1222846A1 (zh) | 取代的苄基吡唑 | |
| HK1221717A1 (zh) | 取代的苄基吡唑 | |
| IL237190A0 (en) | Pyrazoles are converted as n-type calcium channel blockers | |
| HK1222393A1 (zh) | 新的喹啉取代的化合物 | |
| LT3060041T (lt) | Prostaciklino junginiai | |
| GB201311891D0 (en) | Novel compound | |
| IL237191A0 (en) | Pyrazoles are converted as n-type calcium channel blockers | |
| HRP20171890T1 (hr) | Supstituirani imidazopiridazini | |
| EP2968338A4 (en) | NEW USES | |
| IL237192A0 (en) | Pyrrolopyrazoles as n-type calcium channel blockers | |
| EP2956141A4 (en) | NEW USES | |
| HK1223362A1 (zh) | 取代的吡唑並吡啶胺 | |
| GB2516136B (en) | Colenterazine analogs | |
| HK1220972A1 (zh) | 取代的噻唑並嘧啶 | |
| AP2016009303A0 (en) | Substituted piperidinyl-tetrahydroquinolines | |
| SG10201407223XA (en) | Encoder | |
| HK1217690A1 (zh) | 作爲 型鈣通道阻滯劑的環戊基吡唑 | |
| IL243683A0 (en) | Imidazoles are converted as n-type calcium channel blockers | |
| GB201305329D0 (en) | Encapsulation System | |
| SG11201602134QA (en) | Encapsulation | |
| SG10201404283UA (en) | Semiconductor structure | |
| SG10201404290YA (en) | Semiconductor structure | |
| GB201310577D0 (en) | Secnidazole | |
| GB201308011D0 (en) | Calcium supplement | |
| GB201322171D0 (en) | Java turn-snap |